Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
404.21
+12.57 (3.21%)
At close: Oct 1, 2025, 4:00 PM EDT
403.50
-0.71 (-0.18%)
After-hours: Oct 1, 2025, 6:19 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts that cover Vertex Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $493.64, which forecasts a 22.12% increase in the stock price over the next year. The lowest target is $405 and the highest is $575.
Price Target: $493.64 (+22.12%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 8 | 8 | 8 |
| Buy | 6 | 6 | 6 | 6 | 6 | 8 |
| Hold | 10 | 11 | 11 | 11 | 10 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 27 | 26 | 25 | 24 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $458 → $456 | Hold → Buy | Upgrades | $458 → $456 | +12.81% | Sep 25, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $510 → $475 | Buy | Maintains | $510 → $475 | +17.51% | Sep 11, 2025 |
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Sep 3, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $424 → $411 | Hold | Maintains | $424 → $411 | +1.68% | Aug 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $558 → $546 | Strong Buy | Maintains | $558 → $546 | +35.08% | Aug 6, 2025 |
Financial Forecast
Revenue This Year
12.22B
from 11.02B
Increased by 10.90%
Revenue Next Year
13.39B
from 12.22B
Increased by 9.57%
EPS This Year
18.41
from -2.08
EPS Next Year
20.79
from 18.41
Increased by 12.95%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.7B | 15.1B | |||
| Avg | 12.2B | 13.4B | |||
| Low | 11.6B | 11.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.6% | 23.4% | |||
| Avg | 10.9% | 9.6% | |||
| Low | 5.3% | -4.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.77 | 27.63 | |||
| Avg | 18.41 | 20.79 | |||
| Low | 16.63 | 17.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 50.1% | |||
| Avg | - | 12.9% | |||
| Low | - | -2.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.